The global sarcopenia treatment market is anticipated to witness significant growth owing to rising geriatric population worldwide. With age, muscle loss or sarcopenia becomes common and if left untreated can negatively impact mobility and quality of life. Sarcopenia treatments aim to help prevent or slow down muscle loss through lifestyle changes, supplements and medications.

Sarcopenia is the degenerative loss of skeletal muscle mass and strength associated with aging. It is a significant cause of physical frailty and reduced quality of life in the elderly population. The most common symptoms include fatigue, weakness, slowed gait and physical impairment. Currently, there is no approved drug for Sarcopenia Treatment Market Size by regulatory agencies and the primary treatment strategies are lifestyle and dietary modifications. Protein supplements containing essential amino acids like creatine, HMB and vitamins D & B are commonly recommended to promote muscle synthesis. Some prescription drugs targeted at conditions like osteoporosis have shown benefits inmaintaining muscle mass as well.

The Global sarcopenia treatment market is estimated to be valued at US$ 3.47 Bn in 2024 and is expected to exhibit a CAGR of 9.5% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the sarcopenia treatment market are Yokogawa, General Electric, Rockwell Automation, MAVERICK Technologies, Emerson, Siemens, Rudolph Technologies, Honeywell International, ABB, Schneider Electric, Aspen Technology.

Some of the key opportunities in the market include development of novel drugs for effective treatment, nutritional supplements targeting various genes and pathways involved in sarcopenia, availability of advanced diagnostic tools to better identify patients.

The leading players are focused on global expansion through collaboration with local players, acquisitions and by establishing manufacturing and distribution facilities across major markets to tap into new growth avenues.

Market Drivers
Rising geriatric population worldwide susceptible to age-related muscle loss is a major driver as around 5-13% of people aged 60 and over are impacted by sarcopenia. By 2050, over 16% of the world's population is projected to be aged 65 and above.

Market Restraints
High costs associated with the limited treatment options available and lack of approved drugs are a major restraint. Underdiagnosis is also a challenge due to lack of standardized diagnostic criteria and testing. Reimbursement issues in some regions further limits widespread adoption of treatments.
Segment Analysis
The sarcopenia treatment market is dominated by the protein supplements segment. This is because protein supplements are the most effective and easily available treatment option for sarcopenia. Protein supplements help in building muscles and preventing muscle loss. Whey protein supplements are the most popular as they digest quickly and are easily absorbed by the body. The demand for whey protein supplements is high among both men and women aged 60 years and above who are at a high risk of sarcopenia.

Global Analysis
North America dominates the global sarcopenia treatment market and accounted for the largest revenue share in 2024. This is attributed to high awareness regarding sarcopenia and availability of advanced treatment options in the region. Moreover, adoption of nutritional supplements for sarcopenia prevention and management is high among the aging population in the US and Canada. Europe is also a major sarcopenia treatment market. However, Asia Pacific is expected to grow at the fastest pace during the forecast period. Increasing geriatric population, improving healthcare infrastructure and rising medical tourism are fueling the market growth in Asia Pacific countries like China, Japan and India.
Get More Insights On Sarcopenia Treatment Market